Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineered proteins as specific binding reagents.

H Kaspar Binz1, Andreas Plückthun

  • 1Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.

Current Opinion in Biotechnology
|July 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

EMBO molecular medicine·2026
Same author

Semi-automated Ribosome Display for High-Throughput DARPin Binder Selection.

New biotechnology·2026
Same author

Transcriptional transactivation turns human iPSC-derived macrophages into an adenovirus-producing cell state.

Journal of virology·2026
Same author

DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Cryo-EM structures of higher order Gephyrin oligomers reveal principles of inhibitory postsynaptic scaffold organization.

Nature communications·2026
Same author

Pre-assembly of biomolecular condensate seeds drives RSV replication.

Nature·2026

Monoclonal antibodies are being challenged by synthetic antibody libraries and engineered protein scaffolds. These novel binding molecules offer promising alternatives for research, diagnostics, and therapeutic applications.

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Immunology

Background:

  • Monoclonal antibodies (mAbs) have been the standard for binding proteins for three decades, used in research, diagnostics, and therapy.
  • Synthetic antibody libraries and advanced selection technologies present significant competition to traditional mAbs.
  • Advances in understanding natural binding proteins and protein engineering fuel the development of new binding molecules.

Purpose of the Study:

  • To explore alternative protein architectures beyond antibodies for generating designed binding molecules.
  • To evaluate the potential of novel protein scaffolds as alternatives to mAbs.
  • To highlight the impact of protein engineering and selection technologies on binding molecule development.

Main Methods:

  • Leveraging increased understanding of natural binding proteins.

Related Experiment Videos

  • Utilizing advances in protein engineering, selection, and evolution technologies.
  • Exploring diverse protein architectures for binding molecule generation.

    • Main Results:

    • Identification of valuable protein-binding scaffolds.
    • Demonstration of engineered protein scaffolds as viable alternatives to antibodies.
    • Validation of advanced selection and evolution technologies in generating binding molecules.

    Conclusions:

    • Engineered protein scaffolds show significant promise as alternatives to monoclonal antibodies.
    • These novel scaffolds have potential applications in biotechnology and clinical settings.
    • The field is moving towards diverse protein architectures for designed binding molecules.